In a phase II, multicenter, non-randomized, open-label study (BRF113928), a total of 84 previously treated (N. 78) and untreated (N. 6) patients with stage IV metastatic BRAF V600E-positive NSCLC were enrolled to test the efficacy of dabrafenib [106]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.